Skip to main content
An official website of the United States government
Español
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

Reblozyl

(REB-loh-zil)
A drug used to treat anemia in adults with certain types of myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms who need regular red blood cell transfusions and whose anemia did not respond to or cannot be treated with an erythropoiesis-stimulating agent. Reblozyl is also used to treat anemia in adults with beta thalassemia (an inherited blood disorder) who need regular red blood cell transfusions. It is also being studied in the treatment of other conditions. Reblozyl helps the bone marrow make more red blood cells. It is a type of antianemic and a type of recombinant fusion protein. Also called luspatercept.
Search NCI's Dictionary of Cancer Terms